Researchers show potential for new cancer detection and therapy method

April 22, 2010, University of Missouri-Columbia
Raghuraman Kannan (left), and Kattesh Katti, faculty members in the department of radiology at the University of Missouri, have discovered gold nanoparticles that could be used to treat a variety of cancers. Credit: University of Missouri

University of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans.

"When injected into the body, the Gastrin Releasing Peptide (GRP) receptor serves as a signaling device to the gold nanoparticle, which allows for targeted delivery to the tumor site," said Kattesh Katti, PhD, who wrote the article with Raghuraman Kannan, PhD. "Consequently, the radiotherapeutic properties of such nanoparticles also provides valuable imaging and therapeutic tools that can be used for early and therapy in various human cancers."

Because GRP receptor mediated imaging and the radiotherapy specifically targets cancer cells, patients could benefit from a more effective treatment with fewer side effects. GRP receptors are abundant in prostate, breast and small lung cancer cells, and the effectiveness of Katti and Kannan's has been proved in numerous studies.

"The development of GRP-receptor specific gold nanoparticles and proof of cancer receptor specificity in living subjects, as described by Drs. Katti and Kannan, is a significant and critical step toward the utility of engineered gold nanoparticles in molecular imaging and therapy of various cancers," said Institute of Medicine member Sanjiv Sam Gambhir, MD, PhD, Virginia and D. K. Ludwig Professor, as well as director of the Molecular Imaging Program and Canary Center for Cancer Early Detection at Stanford University.

Katti, Kannan, and others with the MU School of Medicine Department of Radiology have been researching the development of tumor specific gold nanoparticles for more than five years.

"This discovery presents a plethora of realistic opportunities for clinical translation, not only in the development of nanomedicine-based diagnostic technologies for early stage detection but also for therapies for treating tumors in prostate, breast and small cell lung cancer," Kannan said.

Kannan and Katti have developed a library of more than 85 engineered nanoparticles for use in and therapy. With scientists at the MU Research Reactor (MURR), the most powerful university reactor in the world, they have developed cancer specific therapeutic radioactive gold nanoparticles. MURR is one of only a few sites worldwide able to produce cancer targeting gold nanoparticles.

More information: The article, titled "Bombesin Functionalized Gold Nanoparticles Show In vitro and In vivo Cancer Receptor Specificity," is available online at: … /1002143107.abstract

Related Stories

Recommended for you

More than 2,500 cancer cases a week could be avoided

March 23, 2018
More than 135,500 cases of cancer a year in the UK could be prevented through lifestyle changes, according to new figures from a Cancer Research UK landmark study published today.

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Researchers examine role of fluid flow in ovarian cancer progression

March 22, 2018
New research from Virginia Tech is moving physicians closer to pinpointing a predictor of ovarian cancer, which could lead to earlier diagnosis of what is know as the "silent killer."

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.